Lantheus Holdings, Inc. (NASDAQ:LNTH) is MPM Bioimpact LLC’s 8th Largest Position

MPM Bioimpact LLC grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 57.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 236,213 shares of the medical equipment provider’s stock after buying an additional 86,031 shares during the quarter. Lantheus comprises approximately 3.0% of MPM Bioimpact LLC’s holdings, making the stock its 8th largest holding. MPM Bioimpact LLC’s holdings in Lantheus were worth $21,132,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kestra Investment Management LLC purchased a new stake in Lantheus in the fourth quarter worth $27,000. Summit Securities Group LLC purchased a new stake in Lantheus in the fourth quarter worth $37,000. UMB Bank n.a. lifted its stake in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares during the period. Parkside Financial Bank & Trust lifted its stake in Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after acquiring an additional 280 shares during the period. Finally, 1620 Investment Advisors Inc. purchased a new stake in Lantheus in the fourth quarter worth $125,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Lantheus stock opened at $78.95 on Wednesday. The company has a 50 day moving average price of $98.73 and a 200-day moving average price of $93.82. Lantheus Holdings, Inc. has a fifty-two week low of $75.00 and a fifty-two week high of $126.89. The company has a market capitalization of $5.41 billion, a PE ratio of 13.14 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $372.76 million during the quarter, compared to analysts’ expectations of $377.37 million. During the same quarter in the prior year, the company posted $1.69 earnings per share. Lantheus’s quarterly revenue was up .8% compared to the same quarter last year. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity

In related news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 63,109 shares of company stock worth $6,016,046. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on LNTH. Truist Financial reduced their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a report on Thursday, May 8th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.